NMS-P118 is a potent, orally available, and highly selectivePARP-1Inhibitor forcancertherapy.

NMS-P118 is found to be less myelotoxicin vitrothan olaparib (now marketed as Lynparza), a dual PARP-1/-2 inhibitor. NMS-P118 proves to be metabolically stable, it modestly inhibites two cytochrome P450 family members (CYP-2B6 IC₅₀: 8.15 μM; CYP-2D6 IC₅₀: 9.51 μM) out of eight isoforms tested. Its ability in hampering the proliferation of bone marrow cells is from 5 to >60 times lower then olaparib according to the species^[1].

NMS-P118 is a potent (K_D=0.009 μM) PARP-1 inhibitor, showing 150-fold selectivity over PARP-2 (K_D=1.39 μM). NMS-P118 possesses excellent pharmacokinetic profile and nearly complete oral bioavailability both in mice and rats. It proved to be highly efficaciousin vivoboth as single agent in MDA-MB-436 human breast cancer tumors and in combination with temozolomide in CAPAN-1 human pancreatic tumors growing as xenografts in the mouse. The compound is well tolerated at highly efficacious doses and is endowed with an excellent ADME profile^[1].

395.42

Solid

C₂₀H₂₄F₃N₃O₂

1262417-51-5

Room temperature in continental US; may vary elsewhere.

DMSO : 16 mg/mL(40.46 mM;Need ultrasonic and warming)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。